Gastric Emptying Modulation GLP2 transiently delays gastric emptying, similar to selective GLP-1 receptor agonists: Slowed rate of nutrient absorption from the gastrointestinal tract Reduced postprandial glucose excursions Effect is most pronounced after initial doses and diminishes with continued treatment Contributes to improved glycemic control through multiple complementary mechanisms Central Nervous System Effects Appetite Regulation Both GIP and GLP-1 receptors are expressed in brain regions controlling appetite and food intake: Reduced food intake and appetite through central nervous system receptor activation Promotion of satiety signals leading to decreased caloric consumption Potential modulation of reward-related feeding behaviors Weight loss effects that appear mediated through both homeostatic and hedonic feeding pathways Clinical trials have demonstrated substantial weight reduction, with participants experiencing decreased appetite as a commonly reported effect of GLP2 treatment
In clinical trials of FDA-approved medications used alongside diet and exercise: Participants taking Wegovy (semaglutide 2.4 mg) lost an average of about 15% of body weight over 68 weeks. Participants taking Zepbound (tirzepatide 15 mg) lost an average of about 20% of body weight over 72 weeks. These are average results observed under clinical trial conditions
Because no generic version exists, out-of-pocket expenses can be steep
He switched to tirzepatide, the active ingredient in Eli Lillys Zepbound, at a dosage that cost $450 a month, then stepped up to a higher dosage at $550
This dual action improves insulin response and may affect fat metabolism, which helps explain the stronger weightloss effect seen in trials, as outlined in this mechanism comparison of tirzepatide and semaglutide
This directly affects your monthly cost
